De Novo myelodysplastic syndromes in patients 20–50 years old are enriched for adverse risk features Journal Article


Authors: Epstein-Peterson, Z. D.; Spitzer, B.; Derkach, A.; Arango, J. E.; McCarter, J. G. W.; Medina-Martínez, J. S.; McGovern, E.; Farnoud, N. R.; Levine, R. L.; Tallman, M. S.
Article Title: De Novo myelodysplastic syndromes in patients 20–50 years old are enriched for adverse risk features
Abstract: Data concerning the treatment approach and clinical outcomes in younger patients with myelodysplastic syndromes (MDS) are lacking. Furthermore, published results from genomic profiling in the young adult MDS population are few. We identified patients aged 20–50 at diagnosis evaluated for de novo MDS at our institution over a 32-year period. Clinical information and results from sequencing panels were extracted for analysis. 68 eligible patients were found, including 32% with multilineage dysplasia and 29% with excess blasts-2 WHO subtypes. Revised International Prognostic Scoring System for MDS (IPSS-R) categorization had 47% high/very high-risk, and this classification held prognostic significance. The median overall survival was 59 months, and most patients (75%) underwent allogeneic hematopoietic cell transplantation (alloHCT). Thirty-four patients had mutational profiling; the most commonly mutated gene was TP53 and most commonly altered gene category was epigenetic regulators. Younger patients with de novo MDS represented a unique subset with high-risk disease features (adverse cytogenetics, higher R-IPSS) frequently observed along with alterations in TP53 and genes related to epigenetic and transcription pathways. © 2022 Elsevier Ltd
Keywords: adult; middle aged; young adult; genetics; mutation; risk factors; hematopoietic stem cell transplantation; risk factor; myelodysplastic syndrome; myelodysplastic syndromes; procedures; humans; prognosis; human; mutational profiling; adolescent/young adult patients
Journal Title: Leukemia Research
Volume: 117
ISSN: 0145-2126
Publisher: Elsevier Ltd  
Date Published: 2022-06-01
Start Page: 106857
Language: English
DOI: 10.1016/j.leukres.2022.106857
PUBMED: 35598475
PROVIDER: scopus
PMCID: PMC9875161
DOI/URL:
Notes: Article -- Export Date: 1 July 2022 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics